C-reactive protein: How conformational changes influence inflammatory properties
暂无分享,去创建一个
H. Bannasch | K. Peter | G. Stark | G. Stark | S. Eisenhardt | J. Thiele | S. Eisenhardt
[1] A. Agrawal,et al. Binding of the monomeric form of C-reactive protein to enzymatically-modified low-density lipoprotein: effects of phosphoethanolamine. , 2009, Clinica chimica acta; international journal of clinical chemistry.
[2] A. Murphy,et al. Dissociation of Pentameric to Monomeric C-Reactive Protein on Activated Platelets Localizes Inflammation to Atherosclerotic Plaques , 2009, Circulation research.
[3] J. Filep,et al. Monomeric C‐reactive protein activates endothelial cells via interaction with lipid raft microdomains , 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[4] J. Danesh,et al. C‐reactive protein and coronary heart disease: a critical review , 2008, Journal of internal medicine.
[5] K. Matthews,et al. Ethnic differences in C-reactive protein concentrations. , 2008, Clinical chemistry.
[6] Claudio J. Verzilli,et al. Bayesian meta-analysis of genetic association studies with different sets of markers. , 2008, American journal of human genetics.
[7] K. Peter,et al. Subtractive single-chain antibody (scFv) phage-display: tailoring phage-display for high specificity against function-specific conformations of cell membrane molecules , 2007, Nature Protocols.
[8] J. Tegnér,et al. Human C-reactive protein slows atherosclerosis development in a mouse model with human-like hypercholesterolemia , 2007, Proceedings of the National Academy of Sciences.
[9] L. Lerman,et al. Local Production of Lipoprotein-Associated Phospholipase A2 and Lysophosphatidylcholine in the Coronary Circulation: Association With Early Coronary Atherosclerosis and Endothelial Dysfunction in Humans , 2007, Circulation.
[10] C. Bode,et al. Generation of activation-specific human anti-alphaMbeta2 single-chain antibodies as potential diagnostic tools and therapeutic agents. , 2007, Blood.
[11] W. Lu,et al. Cell membranes and liposomes dissociate C‐reactive protein (CRP) to form a new, biologically active structural intermediate: mCRPm , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[12] M. Criqui,et al. Gender and C-reactive protein: data from the Multiethnic Study of Atherosclerosis (MESA) cohort. , 2006, American heart journal.
[13] S. Simon,et al. CRP promotes monocyte-endothelial cell adhesion via Fcgamma receptors in human aortic endothelial cells under static and shear flow conditions. , 2006, American journal of physiology. Heart and circulatory physiology.
[14] Steven V. Ley,et al. Targeting C-reactive protein for the treatment of cardiovascular disease , 2006, Nature.
[15] Paul M Ridker,et al. C-reactive protein and other emerging blood biomarkers to optimize risk stratification of vulnerable patients. , 2006, Journal of the American College of Cardiology.
[16] M. Sabatine,et al. Lipoprotein-Associated Phospholipase A2 and Its Association With Cardiovascular Outcomes in Patients With Acute Coronary Syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy–Thrombolysis In Myocardial Infarction) Trial , 2006, Circulation.
[17] J. Zhao,et al. Effect of Modified C-Reactive Protein on Complement Activation: A Possible Complement Regulatory Role of Modified or Monomeric C-Reactive Protein in Atherosclerotic Lesions , 2006, Arteriosclerosis, thrombosis, and vascular biology.
[18] R. Wander,et al. Production of Modified C-Reactive Protein in U937-Derived Macrophages , 2005, Experimental biology and medicine.
[19] J. Filep,et al. Loss of pentameric symmetry of C‐reactive protein induces interleukin‐8 production through peroxynitrite signaling in human neutrophils , 2005, Circulation research.
[20] E. Yeh,et al. Release of C-reactive protein in response to inflammatory cytokines by human adipocytes: linking obesity to vascular inflammation. , 2005, Journal of the American College of Cardiology.
[21] C. Wanner,et al. Native C-Reactive Protein Increases Whereas Modified C-Reactive Protein Reduces Atherosclerosis in Apolipoprotein E–Knockout Mice , 2005, Circulation.
[22] J. Jukema,et al. No Effect of C-Reactive Protein on Early Atherosclerosis Development in Apolipoprotein E*3-Leiden/Human C-Reactive Protein Transgenic Mice , 2005, Arteriosclerosis, thrombosis, and vascular biology.
[23] M. Blettner,et al. Role of C-Reactive Protein in Atherogenesis: Can the Apolipoprotein E Knockout Mouse Provide the Answer? , 2005, Arteriosclerosis, thrombosis, and vascular biology.
[24] Arjun Deb,et al. Proapoptotic, Antimigratory, Antiproliferative, and Antiangiogenic Effects of Commercial C-Reactive Protein on Various Human Endothelial Cell Types In Vitro: Implications of Contaminating Presence of Sodium Azide in Commercial Preparation , 2005, Circulation research.
[25] C. Sabin,et al. Transgenic human C-reactive protein is not proatherogenic in apolipoprotein E-deficient mice. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[26] J. Giddings,et al. C-Reactive Protein–Induced In Vitro Endothelial Cell Activation Is an Artefact Caused by Azide and Lipopolysaccharide , 2005, Arteriosclerosis, thrombosis, and vascular biology.
[27] L. Kuo,et al. C-Reactive Protein Inhibits Endothelium-Dependent NO-Mediated Dilation in Coronary Arterioles by Activating p38 Kinase and NAD(P)H Oxidase , 2005, Arteriosclerosis, thrombosis, and vascular biology.
[28] P. Reitsma,et al. Activation of Inflammation and Coagulation After Infusion of C-Reactive Protein in Humans , 2005, Circulation research.
[29] A. Hofman,et al. Lipoprotein-Associated Phospholipase A2 Activity Is Associated With Risk of Coronary Heart Disease and Ischemic Stroke: The Rotterdam Study , 2005, Circulation.
[30] J. Kemp,et al. Human C-Reactive Protein Increases Cerebral Infarct Size after Middle Cerebral Artery Occlusion in Adult Rats , 2004, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[31] J. Filep,et al. Opposing Effects of C-Reactive Protein Isoforms on Shear-Induced Neutrophil-Platelet Adhesion and Neutrophil Aggregation in Whole Blood , 2004, Circulation.
[32] D. Lang,et al. C-Reactive Protein-Induced In Vitro Vasorelaxation Is an Artefact Caused by the Presence of Sodium Azide in Commercial Preparations , 2004, Arteriosclerosis, thrombosis, and vascular biology.
[33] S. Devaraj,et al. C-Reactive Protein: Risk Marker or Mediator in Atherothrombosis? , 2004, Hypertension.
[34] J. Filep,et al. Conformational Rearrangement in C-Reactive Protein Is Required for Proinflammatory Actions on Human Endothelial Cells , 2004, Circulation.
[35] Richard D. Weisel,et al. C-Reactive Protein Upregulates Complement-Inhibitory Factors in Endothelial Cells , 2004, Circulation.
[36] Lan Li,et al. C-Reactive Protein Accelerates the Progression of Atherosclerosis in Apolipoprotein E–Deficient Mice , 2004, Circulation.
[37] C. Wanner,et al. Tubular staining of modified C-reactive protein in diabetic chronic kidney disease. , 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[38] E. Yeh,et al. Inflammatory Cytokines Stimulated C-Reactive Protein Production by Human Coronary Artery Smooth Muscle Cells , 2003, Circulation.
[39] Hongwei Wang,et al. Two-dimensional crystallization of rabbit C-reactive protein monomeric subunits. , 2003, Acta crystallographica. Section D, Biological crystallography.
[40] S. Verma,et al. C-Reactive Protein Upregulates Angiotensin Type 1 Receptors in Vascular Smooth Muscle , 2003, Circulation.
[41] Hitoshi Nishizawa,et al. Reciprocal Association of C-Reactive Protein With Adiponectin in Blood Stream and Adipose Tissue , 2003, Circulation.
[42] Edward T H Yeh,et al. Coming of age of C-reactive protein: using inflammation markers in cardiology. , 2003, Circulation.
[43] Yu-ling,et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. , 2003, Circulation.
[44] S. Devaraj,et al. C-Reactive Protein Increases Plasminogen Activator Inhibitor-1 Expression and Activity in Human Aortic Endothelial Cells: Implications for the Metabolic Syndrome and Atherothrombosis , 2003, Circulation.
[45] L. Lerman,et al. C-Reactive Protein Relaxes Human Vessels In Vitro , 2002, Arteriosclerosis, thrombosis, and vascular biology.
[46] J. Filep,et al. Loss of Pentameric Symmetry of C-reactive Protein Is Associated with Delayed Apoptosis of Human Neutrophils* , 2002, The Journal of Biological Chemistry.
[47] J. Witztum,et al. C-reactive protein binds to both oxidized LDL and apoptotic cells through recognition of a common ligand: Phosphorylcholine of oxidized phospholipids , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[48] Sridevi Devaraj,et al. Demonstration That C-Reactive Protein Decreases eNOS Expression and Bioactivity in Human Aortic Endothelial Cells , 2002, Circulation.
[49] N. Brot,et al. I-PLA2 Activation during Apoptosis Promotes the Exposure of Membrane Lysophosphatidylcholine Leading to Binding by Natural Immunoglobulin M Antibodies and Complement Activation , 2002, The Journal of experimental medicine.
[50] J. Borensztajn,et al. Macrophage uptake of low-density lipoprotein bound to aggregated C-reactive protein: possible mechanism of foam-cell formation in atherosclerotic lesions. , 2002, The Biochemical journal.
[51] C. Mold,et al. Protection from Streptococcus pneumoniae Infection by C-Reactive Protein and Natural Antibody Requires Complement But Not Fcγ Receptors1 , 2002, The Journal of Immunology.
[52] S. Barnum,et al. Experimental Allergic Encephalomyelitis Is Inhibited in Transgenic Mice Expressing Human C-Reactive Protein1 , 2002, The Journal of Immunology.
[53] J. Filep,et al. Loss of Pentameric Symmetry of C-Reactive Protein Is Associated with Promotion of Neutrophil-Endothelial Cell Adhesion1 , 2001, The Journal of Immunology.
[54] K. Kayaba,et al. Distribution of serum C-reactive protein and its association with atherosclerotic risk factors in a Japanese population : Jichi Medical School Cohort Study. , 2001, American journal of epidemiology.
[55] J. Salmon,et al. Human receptors for immunoglobulin G: key elements in the pathogenesis of rheumatic disease. , 2001, Arthritis and rheumatism.
[56] V. Hombach,et al. C-Reactive Protein–Mediated Low Density Lipoprotein Uptake by Macrophages: Implications for Atherosclerosis , 2001, Circulation.
[57] P. Mcgeer,et al. Generation of C-reactive protein and complement components in atherosclerotic plaques. , 2001, The American journal of pathology.
[58] J. Weiser,et al. Expression of C-Reactive Protein in the Human Respiratory Tract , 2001, Infection and Immunity.
[59] N. Brot,et al. C-Reactive Protein Binds to Apoptotic Cells, Protects the Cells from Assembly of the Terminal Complement Components, and Sustains an Antiinflammatory Innate Immune Response , 2000, The Journal of experimental medicine.
[60] James T. Willerson,et al. Direct Proinflammatory Effect of C-Reactive Protein on Human Endothelial Cells , 2000, Circulation.
[61] J. Volanakis,et al. Human C-Reactive Protein Is Protective against Fatal Salmonella enterica Serovar Typhimurium Infection in Transgenic Mice , 2000, Infection and Immunity.
[62] Kai Simons,et al. Lipid rafts and signal transduction , 2000, Nature Reviews Molecular Cell Biology.
[63] P. Ridker,et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. , 2000, The New England journal of medicine.
[64] J. Radosevich,et al. Immunohistochemical localization of modified C-reactive protein antigen in normal vascular tissue. , 2000, The American journal of the medical sciences.
[65] M. Pepys,et al. C-Reactive Protein and Complement Are Important Mediators of Tissue Damage in Acute Myocardial Infarction , 1999, The Journal of experimental medicine.
[66] S. Bhakdi,et al. Complement and atherogenesis: binding of CRP to degraded, nonoxidized LDL enhances complement activation. , 1999, Arteriosclerosis, thrombosis, and vascular biology.
[67] C. Mold,et al. Regulation of complement activation by C-reactive protein. , 1999, Immunopharmacology.
[68] J. Kresl,et al. Inhibition of Mouse Mammary Adenocarcinoma (EMT6) Growth and Metastases in Mice by a Modified Form of C-Reactive Protein , 1999, Tumor Biology.
[69] L. Potempa,et al. Biodistribution and clearance of 125I-labeled C-reactive protein and 125I-labeled modified C-reactive protein in CD-1 mice. , 1998, Drug metabolism and disposition: the biological fate of chemicals.
[70] W. Koenig,et al. C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries. , 1998, Arteriosclerosis, thrombosis, and vascular biology.
[71] J. Filep,et al. Prevention of In vitro neutrophil adhesion to endothelial cells through shedding of L-selectin by C-reactive protein and peptides derived from C-reactive protein. , 1997, The Journal of clinical investigation.
[72] D. Xia,et al. Transgenic mice expressing rabbit C-reactive protein are resistant to endotoxemia. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[73] A. Shrive,et al. Structure solution of C-reactive proteins: molecular replacement with a twist. , 1996, Acta crystallographica. Section D, Biological crystallography.
[74] J. Wright,et al. Expression of C-reactive protein by alveolar macrophages. , 1996, Journal of immunology.
[75] Dongxiao Zhang,et al. STAT3 Participates in Transcriptional Activation of the C-reactive Protein Gene by Interleukin-6 (*) , 1996, The Journal of Biological Chemistry.
[76] W. Liles,et al. Glucocorticoids inhibit apoptosis of human neutrophils. , 1995, Blood.
[77] J. Volanakis,et al. Human C-reactive protein is protective against fatal Streptococcus pneumoniae infection in transgenic mice. , 1995, Journal of immunology.
[78] M. Pepys,et al. The pentraxins, C-reactive protein and serum amyloid P component, are cleared and catabolized by hepatocytes in vivo. , 1994, The Journal of clinical investigation.
[79] R W Alexander,et al. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. , 1994, Circulation research.
[80] H. Tilg,et al. Antiinflammatory properties of hepatic acute phase proteins: preferential induction of interleukin 1 (IL-1) receptor antagonist over IL-1 beta synthesis by human peripheral blood mononuclear cells , 1993, The Journal of experimental medicine.
[81] C. Haslett,et al. Inhibition of apoptosis and prolongation of neutrophil functional longevity by inflammatory mediators , 1993, Journal of leukocyte biology.
[82] A. Mantovani,et al. Modulation of granulocyte survival and programmed cell death by cytokines and bacterial products. , 1992, Blood.
[83] G. Lozanski,et al. Induction of inflammatory cytokine release from cultured human monocytes by C-reactive protein. , 1992, Cytokine.
[84] Therese M. Murphy,et al. Extrahepatic transcription of human C-reactive protein , 1991, The Journal of experimental medicine.
[85] H. Gewurz,et al. Identification and partial characterization of multiple native and neoantigenic epitopes of human C-reactive protein by using monoclonal antibodies. , 1989, Journal of immunology.
[86] H. Gewurz,et al. Preferential expression of neo-CRP epitopes on the surface of human peripheral blood lymphocytes. , 1988, Cellular immunology.
[87] H. Gewurz,et al. Expression of a C-reactive protein neoantigen (neo-CRP) in inflamed rabbit liver and muscle. , 1988, Clinical immunology and immunopathology.
[88] H. Gewurz,et al. Expression, detection and assay of a neoantigen (Neo-CRP) associated with a free, human C-reactive protein subunit. , 1987, Molecular immunology.
[89] L. Baum,et al. Brief Definitive Report C-reactive Protein Is Produced by a Small Number of Normal Human Peripheral Blood Lymphocytes , 2022 .
[90] J. Korenberg,et al. Characterization of genomic and complementary DNA sequence of human C-reactive protein, and comparison with the complementary DNA sequence of serum amyloid P component. , 1985, The Journal of biological chemistry.
[91] C. Vigo. Effect of C-reactive protein on platelet-activating factor-induced platelet aggregation and membrane stabilization. , 1985, The Journal of biological chemistry.
[92] H. Gewurz,et al. Antigenic, electrophoretic and binding alterations of human C-reactive protein modified selectively in the absence of calcium. , 1983, Molecular immunology.
[93] A. Feinstein,et al. Low density lipoprotein and very low density lipoprotein are selectively bound by aggregated C-reactive protein , 1982, The Journal of experimental medicine.
[94] J. Volanakis. COMPLEMENT ACTIVATION BY C‐REACTIVE PROTEIN COMPLEXES * , 1982, Annals of the New York Academy of Sciences.
[95] M. Pepys,et al. Solid phase radioimmunoassays for human C-reactive protein. , 1981, Clinica chimica acta; international journal of clinical chemistry.
[96] K. Wirtz,et al. Interaction of C-reactive protein with artificial phosphatidylcholine bilayers , 1979, Nature.
[97] H. Gewurz,et al. Interactions of C-reactive protein with the complement system. II. C- reactive protein-mediated consumption of complement by poly-L-lysine polymers and other polycations , 1975, The Journal of experimental medicine.
[98] J. Volanakis,et al. Interaction of C-reactive protein complexes with the complement system. I. Consumption of human complement associated with the reaction of C-reactive protein with pneumococcal C-polysaccharide and with the choline phosphatides, lecithin and sphingomyelin. , 1974, Journal of immunology.
[99] M. H. Kaplan,et al. Specificity of C-Reactive Protein for Choline Phosphate Residues of Pneumococcal C-Polysaccharide , 1971, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.
[100] G. Moneta. C-Reactive Protein-Bound Enzymatically Modified Low-Density Lipoprotein Does Not Transform Macrophages into Foam Cells , 2010 .
[101] Jing Zhao,et al. Interactions of C-reactive protein with low-density lipoproteins: implications for an active role of modified C-reactive protein in atherosclerosis. , 2006, The international journal of biochemistry & cell biology.
[102] Tarunendu Ghose. Oswald Avery: the professor, DNA, and the Nobel Prize that eluded him. , 2004, Canadian bulletin of medical history = Bulletin canadien d'histoire de la medecine.
[103] B. Haimovich,et al. Phospholipase A2 enzymes regulate alpha IIb beta3-mediated, but not Fc gammaRII receptor-mediated, pp125FAK phosphorylation in platelets. , 1999, Thrombosis and haemostasis.
[104] T. D. Du Clos. The interaction of C-reactive protein and serum amyloid P component with nuclear antigens. , 1996, Molecular biology reports.
[105] M. Shields. A hypothesis resolving the apparently disparate activities of native and altered forms of human C-reactive protein , 1993, Immunologic research.
[106] M. Pepys,et al. Acute phase proteins with special reference to C-reactive protein and related proteins (pentaxins) and serum amyloid A protein. , 1983, Advances in immunology.
[107] A. Feinstein,et al. Isolation and characterization of C-reactive protein and serum amyloid P component in the rat. , 1982, Immunology.
[108] Peter Søgaard,et al. Electromechanical Mapping for Detection of Myocardial Viability in Patients With Ischemic Cardiomyopathy , 2001, Circulation.